Dr. Cezary Mazurek, Computer Scientist, his professional activity has been associated with the development of the Poznan Supercomputing and Networking Center (PCSS) since its establishment in 1993. He served as CEO of PCSS from 2019 to 2024 and at that time he successfully brought it onto the path of developing infrastructure and applications of quantum computing and AI, and is now continuing this thread with a focus on applications in Life Sciences and Personalized Medicine. For over 30 years, he has been involved in the development of Polish and European e-infrastructure for science and is currently one of the most experienced leaders in R&D projects, many of which he has successfully implemented in practice. To date, he has led development of more than 40 national and international R&D projects. His R&D work has focused on integrating various specialized software components into consistent systems for digital science with emphasis on software governance. In recent years, he has been involved in the development of domain research infrastructures, such as for digital humanities, as well as for personalized medicine. 

Cezary’s scientific activities mainly focus on applying machine learning methods for early detection of disease development mechanisms. A solution led by him to support pre-symptomatic diagnosis of glaucoma development using machine learning received patent protection from the Japan Patent Office in 2023 and from European Patent Office in 2025. He is currently extending his interests to advanced methods of data collection and analysis in a digital twin model. He is author or co-author of over 100 papers in professional journals and conference proceedings. Since 2020 the President of Wielkopolska ICT Cluster. Since 2023 the member of GÉANT Association Board of Directors. In 2024 he initiated the establishment of a national consortium EBRAINS-PL and became the member of EBRAINS National Node Board. IEEE Senior Member, member of IEEE Computer Society as well as IEEE Computational Intelligence Society.

Kun-Hsing “Kun” Yu, M.D., Ph.D., is an Associate Professor in the Department of Biomedical Informatics at Harvard Medical School. He pioneered the first fully automated artificial intelligence (AI) algorithm capable of extracting thousands of features from whole-slide pathology images. His research has uncovered molecular mechanisms driving the microscopic phenotypes of tumor cells and identified novel cellular morphologies that predict patient prognosis.

Dr. Yu’s lab integrates multi-omics (e.g., genomics, epigenomics, transcriptomics, and proteomics) profiles with quantitative pathology patterns to predict clinical phenotypes in cancer patients. The AI methods developed by the Yu Lab have been independently validated by over 200 research laboratories worldwide.

His contributions to AI in pathology have earned numerous honors, including the National Institutes of Health (NIH) Maximizing Investigators’ Research Award, Google Research Scholar Award, American Medical Informatics Association New Investigator Award, Harvard Medical School Dean’s Innovation Award, Department of Defense (DoD) Career Development Award, and the American Cancer Society (ACS) Research Scholar Award. He is a Fellow of the American Medical Informatics Association (FAMIA).

Ming-Chin Yu, M.D., Ph.D., is a Professor of Surgery at Chang Gung University and the Vice Superintendent and Director of the Department of Surgery at New Taipei Municipal TuCheng Hospital (operated by Chang Gung Medical Foundation). He is a pioneering leader in hepatobiliary and pancreatic surgery, specializing in laparoscopic techniques and liver transplantation. His research has uncovered critical molecular mechanisms in hepatocellular carcinoma (HCC), including the modulation of the tumor microenvironment via SOX4 and CXCL12, and the identification of circulating biomarkers for early cancer detection.

Dr. Yu’s clinical and research teams integrate genomic profiling with surgical innovation. He has conducted extensive studies on the roles of exosomes and cell-free DNA in cancer progression and is advancing the application of 3D image reconstruction technologies to optimize complex hepatobiliary and pancreatic operations. He has also served as a principal investigator and key collaborator in major international clinical trials evaluating immunotherapy agents such as lenvatinib and pembrolizumab for advanced HCC.

His contributions to medical science and surgical oncology have earned him prestigious recognition, including being listed among the World’s Top 2% Scientists (2023 and 2024) and receiving the 2024 Taiwan Medical Contribution Award. Dr. Yu is an active leader in professional societies such as the Taiwan Liver Cancer Association and the Taiwan Association for Endoscopic Surgery, and he frequently chairs international surgical workshops and forums to help shape the future of hepatobiliary and pancreatic surgery.